BR9910329A - Composto, composição farmacêutica, processo para estimular a liberação do hormÈnio de crescimento da pituitária de um mamìfero, e, uso de um composto - Google Patents

Composto, composição farmacêutica, processo para estimular a liberação do hormÈnio de crescimento da pituitária de um mamìfero, e, uso de um composto

Info

Publication number
BR9910329A
BR9910329A BR9910329-0A BR9910329A BR9910329A BR 9910329 A BR9910329 A BR 9910329A BR 9910329 A BR9910329 A BR 9910329A BR 9910329 A BR9910329 A BR 9910329A
Authority
BR
Brazil
Prior art keywords
compound
growth hormone
stimulate
release
pharmaceutical composition
Prior art date
Application number
BR9910329-0A
Other languages
English (en)
Inventor
Thomas Krusen Hansen
Michael Ankersen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of BR9910329A publication Critical patent/BR9910329A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"COMPOSTO, COMPOSIçãO FARMACêUTICA, PROCESSO PARA ESTIMULAR A LIBERAçãO DO HORMÈNIO DE CRESCIMENTO DA PITUITáRIA DE UM MAMìFERO, E, USO DE UM COMPOSTO" A presenta invenção diz respeito a novos compostos, em particular compostos de piridina 4,4-dissubstituídos e 3,3-dissubstituídos, composições que os contenham e seu uso para tratar distúrbios médicos que resultam de uma deficiência no hormónio de crescimento.
BR9910329-0A 1998-05-11 1999-05-10 Composto, composição farmacêutica, processo para estimular a liberação do hormÈnio de crescimento da pituitária de um mamìfero, e, uso de um composto BR9910329A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK63698 1998-05-11
DKPA199800875 1998-07-01
PCT/DK1999/000260 WO1999058501A1 (en) 1998-05-11 1999-05-10 Compounds with growth hormone releasing properties

Publications (1)

Publication Number Publication Date
BR9910329A true BR9910329A (pt) 2001-01-30

Family

ID=26064372

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9910329-0A BR9910329A (pt) 1998-05-11 1999-05-10 Composto, composição farmacêutica, processo para estimular a liberação do hormÈnio de crescimento da pituitária de um mamìfero, e, uso de um composto

Country Status (23)

Country Link
EP (1) EP1077941B1 (pt)
JP (2) JP4142253B2 (pt)
KR (1) KR100593601B1 (pt)
CN (1) CN1142911C (pt)
AT (1) ATE439346T1 (pt)
AU (1) AU757217B2 (pt)
BR (1) BR9910329A (pt)
CA (1) CA2329881C (pt)
CY (1) CY1109626T1 (pt)
CZ (1) CZ301276B6 (pt)
DE (1) DE69941255D1 (pt)
DK (1) DK1077941T3 (pt)
ES (1) ES2331102T3 (pt)
HU (1) HUP0102071A3 (pt)
IL (2) IL139090A0 (pt)
NO (1) NO318080B1 (pt)
PL (1) PL194560B1 (pt)
PT (1) PT1077941E (pt)
RU (1) RU2243215C2 (pt)
SI (1) SI1077941T1 (pt)
TW (1) TWI222969B (pt)
UA (1) UA72210C2 (pt)
WO (1) WO1999058501A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60021521T4 (de) 1999-09-29 2006-09-21 Ortho-Mcneil Pharmaceutical, Inc. Isonipecotamide zur behandlung von integrin vermittelten störungen
UA73530C2 (uk) * 1999-11-10 2005-08-15 Ново Нордіск А/С Сполука з властивостями вивільнювати гормон росту
US20010020012A1 (en) * 2000-02-01 2001-09-06 Andersen Maibritt Bansholm Use of compounds for the regulation of food intake
AU2002230665A1 (en) 2000-12-06 2002-06-18 Sepracor, Inc. 4,4-disubstituted piperidines for use as dopamine, serotonin and norepinephrine ligands
WO2002079146A2 (en) 2001-03-02 2002-10-10 Bristol-Myers Squibb Company Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
DE10113604A1 (de) * 2001-03-20 2002-10-24 Ibfb Gmbh Privates Inst Fuer B Verfahren zur Spaltung des humanen Wachstumshormons GH
US7081460B2 (en) 2001-04-09 2006-07-25 Ortho-Mcneil Pharmaceutical, Inc. Quinazoline and quinazoline-like compounds for the treatment of integrin-mediated disorders
US6911447B2 (en) 2001-04-25 2005-06-28 The Procter & Gamble Company Melanocortin receptor ligands
FR2827518B1 (fr) * 2001-07-17 2005-07-08 Sod Conseils Rech Applic Utilisation d'extraits de ginkgo biloba pour preparer un medicament destine a traiter la sarcopenie
CA2462200A1 (en) 2001-08-10 2003-02-20 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
US7026335B2 (en) 2002-04-30 2006-04-11 The Procter & Gamble Co. Melanocortin receptor ligands
EP1407779A1 (en) 2002-10-10 2004-04-14 Gastrotech A/S Use of ghrelin for treating low body weight and body fat in gastrectomized individuals
TW200504033A (en) 2002-10-23 2005-02-01 Procter & Gamble Melanocortin receptor ligands
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
EP1735055A1 (en) * 2004-03-30 2006-12-27 Sapphire Therapeutics, Inc. Method of reducing c-reactive protein using growth hormone secretagogues
EP2298760B1 (en) * 2004-06-29 2015-08-05 Helsinn Healthcare S.A. Crystal forms of (3R)-1-(2-methylalanyl-D-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide
AU2005272598B2 (en) * 2004-08-12 2011-11-17 Helsinn Therapeutics (U.S.), Inc. Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
CA2656398A1 (en) * 2006-06-30 2008-01-10 Schering Corporation Substituted piperidines that increase p53 activity and the uses thereof
CA2677399C (en) 2007-02-09 2016-09-13 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor modulators and methods of using the same
WO2012131090A1 (en) 2011-03-31 2012-10-04 Galderma Research & Development Method for treatment of xeroderma pigmentosum
CN114805305B (zh) * 2022-04-20 2024-04-26 成都诺和晟泰生物科技有限公司 一种化合物及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1174504A (zh) * 1993-11-09 1998-02-25 麦克公司 促进生长激素释放的哌啶、吡咯烷和六氢－1h－吖庚因
US5492916A (en) * 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5721250A (en) * 1993-12-23 1998-02-24 Merck & Co. Inc. Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5559128A (en) * 1995-04-18 1996-09-24 Merck & Co., Inc. 3-substituted piperidines promote release of growth hormone
WO1996035713A1 (en) * 1995-05-08 1996-11-14 Pfizer, Inc. Dipeptides which promote release of growth hormone
EP0828754B1 (en) * 1995-05-29 2005-02-02 Pfizer Inc. Dipeptides which promote release of growth hormone
GB2308064A (en) * 1995-10-31 1997-06-18 Merck & Co Inc Treatment of congestive heart failure with a growth hormone secretagogue
WO1997036873A1 (en) * 1996-04-03 1997-10-09 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
DE69734215T2 (de) * 1996-07-22 2006-06-29 Novo Nordisk A/S Verbindungen mit Wachstumshormon-freisetzenden Eigenschaften
WO1998010653A1 (en) * 1996-09-13 1998-03-19 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
JP2001502319A (ja) * 1996-10-15 2001-02-20 藤沢薬品工業株式会社 成長ホルモンの放出を促進するベンズオキセピン誘導体

Also Published As

Publication number Publication date
KR100593601B1 (ko) 2006-06-28
CN1300281A (zh) 2001-06-20
PL194560B1 (pl) 2007-06-29
NO20005668D0 (no) 2000-11-10
AU757217B2 (en) 2003-02-06
ES2331102T3 (es) 2009-12-21
EP1077941B1 (en) 2009-08-12
CY1109626T1 (el) 2014-08-13
RU2243215C2 (ru) 2004-12-27
UA72210C2 (uk) 2005-02-15
DK1077941T3 (da) 2009-12-07
TWI222969B (en) 2004-11-01
SI1077941T1 (sl) 2010-01-29
JP2004500312A (ja) 2004-01-08
CN1142911C (zh) 2004-03-24
JP2008156372A (ja) 2008-07-10
CA2329881C (en) 2010-03-16
JP4142253B2 (ja) 2008-09-03
AU3701099A (en) 1999-11-29
KR20010043422A (ko) 2001-05-25
IL139090A0 (en) 2001-11-25
ATE439346T1 (de) 2009-08-15
HUP0102071A3 (en) 2002-06-28
JP4938708B2 (ja) 2012-05-23
PL344042A1 (en) 2001-09-24
CZ20004129A3 (en) 2001-06-13
NO318080B1 (no) 2005-01-31
WO1999058501A1 (en) 1999-11-18
DE69941255D1 (de) 2009-09-24
IL139090A (en) 2007-03-08
NO20005668L (no) 2001-01-10
EP1077941A1 (en) 2001-02-28
PT1077941E (pt) 2010-07-01
CA2329881A1 (en) 1999-11-18
CZ301276B6 (cs) 2009-12-30
HUP0102071A2 (hu) 2002-03-28

Similar Documents

Publication Publication Date Title
BR9813028A (pt) Agonistas de prostaglandina e seu uso para tratar distúrbios nos ossos
BR9910180A (pt) Composição farmacêutica, processos para o tratamento de uma condição associada com a transmissão reduzida de nicotina, para identificação de um modulador positivo de um agonista receptor nicotìnico e para identificação de um composto, composto, e, uso de um modulador positivo de um agonista receptor nicotìnico
ATE257386T1 (de) Pharmazeutische zusammensetzungen enthaltend eine mischung von selbstvernetzter und nichtselbstvernetzter hyaluronsäure zur behandlung von arthropathien
BR9814435A (pt) Novos esteróides antiestrogênicos e composições farmacêuticas associadas
BR9408377A (pt) Composto composição farmacêutica processo para estimular a liberação de hormônio de crescimento da pituitária e uso do composto
BR0014384A (pt) Compostos para o tratamento da isquémia
BR9714415A (pt) Heterociclos contendo nitrogênio substituìdo como inibidores de proteìnas quinase p38
PT98710A (pt) Processo de preparacao de compostos de indolilo substituidos e de composicoes farmaceuticas que os contem
BR9804437A (pt) Compostos para a osteoporose
BR9913255A (pt) Composto, composição farmacêutica, processo de tratamento de uma condição de doença mediada por metaloproteinase, processo para preparar um composto, e, uso de um composto
EA200001125A1 (ru) Гелеобразные фармацевтические композиции
BRPI0411255A (pt) composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto
BR9807577A (pt) Método para prevenir e retardar o inìcio da doença de alzheimer e sua composição
YU7797A (sh) Kombinovana terapija za osteoporozu
BR9811099A (pt) Inibidores de urocinase
AR012671A1 (es) Composiciones farmaceuticas para el tratamiento o profilaxis de la constipacion, los usos de dichas composiciones y los procesos para prepararlos
ES2107832T3 (es) Una composicion farmaceutica para la administracion intranasal de hidroxocobalamina.
DE3851776D1 (de) Verwendung von IGF-II zur Behandlung von Knochenkrankheiten.
IT1265101B1 (it) Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico
PT82987B (pt) Processo para a preparacao de novos de derivados de acidos carboxilicos bem como de composicoes farmaceuticas que os contem
NO20005668L (no) Forbindelser med veksthormonfrigjörende egenskaper
BR9914158A (pt) Composição antibiótica para o tratamento dos olhos, ouvidos e nariz
PT99435A (pt) Processo para a preparacao de derivados de amino-sulfonil-ureia e de composicoes farmaceuticas que os contem
MX9300586A (es) Nuevos fragmentos de hormona paratiroidea proceso para su preparacion y composiciones farmaceuticas que los contienen.
BR9915951A (pt) Processo para preparação de uma composição farmacêutica para uso como um medicamento antiarritmias com um bloqueio beta adrenérgico controlado, composição farmacêutica, preparação oral e parenteral para tratamento de doenças cardìacas em mamìferos, e, método de tratamento para as mesmas

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT.CL: C07D 211/60, C07D 211/62, C07D 401/06, A61K 31/445, A61K 31/454, A61P 5/06

Ipc: C07D 211/62 (2009.01), C07D 401/06 (2009.01), A61K

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIDO O PEDIDO COM BASE NOS ARTIGOS 8O E 13 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.